Navigation Links
Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201,(Archexin) to Be Presented at the 43rd American Society of Clinical,Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.

The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit www.rexahn.com.

Contact

Rexahn Pharmaceuticals, Inc.
Amanda Sawney, 240-268-5300 x300


'"/>




Page: 1

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... or injury that focuses on repairing the musculoskeletal and neuromuscular systems of the ... on functional restoration, NYDNRehab began providing treatments for physical therapy in New York, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, ... the official relaunch of its community and education hub for women considering fertility ... is to create a safe and welcoming place for women to find cycle ...
(Date:5/24/2016)... Washington, DC (PRWEB) , ... May 24, 2016 ... ... to consumers for 2016 increased by 9.3 million people, or 10% over last ... The number of people covered under group policies was comparatively stable, with a ...
(Date:5/24/2016)... ... 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on ... around the world who do not have access to a toilet, even when they’re on ... dread of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... today announced a licensing relationship that will deliver a new series of Q&A ... will put the medical knowledge and expertise of Harvard Medical School faculty into ...
Breaking Medicine News(10 mins):